Charles Mangani1, Per Ashorn2, Kenneth Maleta3, John Phuka3, Chrissie Thakwalakwa4, Kathryn Dewey5, Mark Manary6, Taneli Puumalainen7, Yin Bun Cheung8. 1. College of Medicine, University of Malawi, Blantyre, Malawi; University of Tampere School of Medicine, Tampere, Finland; cmangani@medcol.mw. 2. University of Tampere School of Medicine, Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Finland, Tampere, Finland; 3. College of Medicine, University of Malawi, Blantyre, Malawi; 4. College of Medicine, University of Malawi, Blantyre, Malawi; University of Tampere School of Medicine, Tampere, Finland; 5. University of California, Davis, Davis, CA; 6. Washington University School of Medicine, St. Louis, MO; 7. Ministry for Social Affairs and Health, Helsinki, Finland; and. 8. Duke-National University of Singapore Graduate Medical School, National University of Singapore, Singapore, Singapore.
Abstract
BACKGROUND: There is evidence to support the use of lipid-based nutrient supplements (LNSs) to promote child growth and development in low-income countries, but there is also a concern regarding the safety of using iron-fortified products in malaria-endemic areas. OBJECTIVE: The objective of this study was to test the hypothesis that 6- to 18-mo-old rural Malawian children receivingiron-containing (6 mg/d) LNSs would not have excess morbidity compared with infants receiving no supplementation. METHODS: A randomized controlled trial allocated 840 children to receivedaily supplementation with 54 g/d LNS with milk protein base (milk-LNS), 54 g/d LNS with soy protein base (soy-LNS), 71 g/d corn-soy blend (CSB), or no supplementation from 6 to 18 mo of age. Morbidity was compared using a non-inferiority margin set at 20% excess morbidity in supplemented groups compared with the nonsupplemented group. RESULTS: Baseline characteristics were similar across groups. The proportion of days with febrile illness between 6 and 18 mo was 4.9%, and there were no differences between the groups: 4.9% (95% CI: 4.3, 5.5%), 4.5% (95% CI: 3.9, 5.1%), 4.7% (95% CI: 4.1, 5.3%), and 5.5% (95% CI: 4.7-6.3%) in the milk-LNS, soy-LNS, CSB, and control groups, respectively. The proportion of days with respiratory problems and diarrhea between 6 and 18 mo also did not differ between groups. Compared with controls, the incident rate ratio (95% CI) for clinical malaria was 0.80 (0.59, 1.09), 0.77 (0.56, 1.06), and 0.79 (0.58, 1.08) in milk-LNS, soy-LNS, and CSB, respectively, with 95% CIs confirming non-inferiority. The incidence of febrile episodes, diarrhea, respiratory problems or admission to hospital, prevalence of malaria parasitemia throughout the follow-up, and mean change in hemoglobin concentration from baseline were also similar between the groups. CONCLUSIONS:Daily supplementation with 54 g of milk-based or soy protein-based LNS or 71 g of CSB did not result in increases in malaria or respiratory morbidity in children in a malaria-endemic setting. However, we could not conclude whether LNSs did or did not increase diarrheal morbidity. This trial was registered at clinicaltrials.gov as NCT00524446.
RCT Entities:
BACKGROUND: There is evidence to support the use of lipid-based nutrient supplements (LNSs) to promote child growth and development in low-income countries, but there is also a concern regarding the safety of using iron-fortified products in malaria-endemic areas. OBJECTIVE: The objective of this study was to test the hypothesis that 6- to 18-mo-old rural Malawian children receiving iron-containing (6 mg/d) LNSs would not have excess morbidity compared with infants receiving no supplementation. METHODS: A randomized controlled trial allocated 840 children to receive daily supplementation with 54 g/d LNS with milk protein base (milk-LNS), 54 g/d LNS with soy protein base (soy-LNS), 71 g/d corn-soy blend (CSB), or no supplementation from 6 to 18 mo of age. Morbidity was compared using a non-inferiority margin set at 20% excess morbidity in supplemented groups compared with the nonsupplemented group. RESULTS: Baseline characteristics were similar across groups. The proportion of days with febrile illness between 6 and 18 mo was 4.9%, and there were no differences between the groups: 4.9% (95% CI: 4.3, 5.5%), 4.5% (95% CI: 3.9, 5.1%), 4.7% (95% CI: 4.1, 5.3%), and 5.5% (95% CI: 4.7-6.3%) in the milk-LNS, soy-LNS, CSB, and control groups, respectively. The proportion of days with respiratory problems and diarrhea between 6 and 18 mo also did not differ between groups. Compared with controls, the incident rate ratio (95% CI) for clinical malaria was 0.80 (0.59, 1.09), 0.77 (0.56, 1.06), and 0.79 (0.58, 1.08) in milk-LNS, soy-LNS, and CSB, respectively, with 95% CIs confirming non-inferiority. The incidence of febrile episodes, diarrhea, respiratory problems or admission to hospital, prevalence of malaria parasitemia throughout the follow-up, and mean change in hemoglobin concentration from baseline were also similar between the groups. CONCLUSIONS: Daily supplementation with 54 g of milk-based or soy protein-based LNS or 71 g of CSB did not result in increases in malaria or respiratory morbidity in children in a malaria-endemic setting. However, we could not conclude whether LNSs did or did not increase diarrheal morbidity. This trial was registered at clinicaltrials.gov as NCT00524446.
Authors: Jai K Das; Rehana A Salam; Yousaf Bashir Hadi; Sana Sadiq Sheikh; Afsah Z Bhutta; Zita Weise Prinzo; Zulfiqar A Bhutta Journal: Cochrane Database Syst Rev Date: 2019-05-02
Authors: Sania Ashraf; Mahfuza Islam; Leanne Unicomb; Mahbubur Rahman; Peter J Winch; Benjamin F Arnold; Jade Benjamin-Chung; Pavani K Ram; John M Colford; Stephen P Luby Journal: Am J Trop Med Hyg Date: 2020-05 Impact factor: 2.345
Authors: Cornelius M Smuts; Tonderayi M Matsungo; Linda Malan; Herculina S Kruger; Marinel Rothman; Jane D Kvalsvig; Namukolo Covic; Karen Joosten; Saskia J M Osendarp; Maaike J Bruins; Leon G J Frenken; Carl J Lombard; Mieke Faber Journal: Am J Clin Nutr Date: 2019-01-01 Impact factor: 7.045
Authors: Jérôme W Somé; Souheila Abbeddou; Elizabeth Yakes Jimenez; Sonja Y Hess; Zinéwendé P Ouédraogo; Rosemonde M Guissou; Stephen A Vosti; Jean-Bosco Ouédraogo; Kenneth H Brown Journal: BMJ Open Date: 2015-09-11 Impact factor: 2.692